Aptose to Participate in Upcoming Investor Conferences
SAN DIEGO and TORONTO, March 03, 2016 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will present at the following upcoming conferences:
-
Cowen & Company 36th Annual Healthcare Conference
Aptose’s corporate presentation is scheduled to take place at 2:00 p.m. ET on Monday, March 7, 2016 in Boston, MA. A corresponding live webcast of the presentation can be accessed by visiting:
-
28th Annual ROTH Conference
Aptose’s corporate presentation is scheduled to take place at 10:30 a.m. ET on Monday, March 14, 2016 in Dana Point, CA. A corresponding live webcast of the presentation can be accessed by visiting:
The audio webcasts will be archived shortly after the live event and will be available for 90 days through the Aptose website at www.aptose.com.
About Aptose Biosciences
Aptose Biosciences is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer research coupled with validated biomarkers to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed to provide additive or synergistic efficacy with existing anti-cancer therapies and regimens without overlapping toxicities. Aptose Biosciences Inc. is listed on NASDAQ under the symbol APTO and on the TSX under the symbol APS. For further information, please visit www.aptose.com.
For further information, please contact: Aptose Biosciences Greg Chow, CFO 647-479-9828 gchow@aptose.com BCC Partners Karen L. Bergman or Susan Pietropaolo 650-575-1509 or 845-638-6290 kbergman@bccpartners.com or spietropaolo@bccpartners.comSource: Aptose Biosciences Inc.
Released March 3, 2016